Advanced searches left 3/3

Metastatic Lung Cancer - Europe PMC

Summarized by Plex Scholar
Last Updated: 23 April 2022

* If you want to update the article please login/register

Differentiation of Reactive Lymph Nodes and Tumor Metastatic Lymph Nodes With 68Ga-FAPI PET/CT in a Patient With Squamous Cell Lung Cancer.

Abstract The preoperative PET/CT in non-small cell lung cancer patients is often confused by false-positive findings of mediastinal lymph node. We also reported 18F-FDG and 68Ga-FAPI PET/CT findings in a patient with squamous cell lung cancer in this case. Due to increased uptake in the expanded right lower lymph node, the increased right lower lymph node was stage IIIA.

Source link: https://europepmc.org/article/MED/35020643


Next-generation Tumor-homing Induced Neural Stem Cells as an Adjuvant to Radiation for the Treatment of Metastatic Lung Cancer.

With a median survival of just a few months, the spread of non-small cell lung cancer to the leptomeninges is devastating. Spheroidal, human-induced neural stem cells secretly harboring the cytotoxic protein, TRAIL, has innate tumoritropic characteristics. HiNeuroS-TRAIL cells migrate to NSCLC tumors, according to in vitro cell recording and post-mortem tissue analysis. Importantly, isobolographic evidence indicates that TRAIL with radiation has a synergistic cytotoxic effect on NSCLC tumors. Following radiation, both NSCLC and hiNeuroS-TRAIL cells demonstrated shifts in genes involved in migration.

Source link: https://europepmc.org/article/MED/35441348


Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice.

To desect PD-1 blockade effectiveness in non-small cell lung cancer, we want to delineate and then integrate both the predictive and prognostic effects of the metastatic-organ landscape. Patients with various organ-specific metastases responded to immunotherapy in a different way than others, and those with brain and adrenal gland metastases lived longer than others [overall survival, 0. 0105; progression-free survival, 0. 0167]. Both predictive and prognostic results of the entire landscape and dissected OS outcomes of NSCLC patients were integrated with PD-1 blockade but not chemotherapy in the OAK training cohort, according to the OAK training cohort. METscore was also applicable to patients receiving PD-1 blockade as first-line therapy both in the clinical trials and in the real-life scenario. Conclusions Organ-specific metastatic landscape served as a potential predictor of immunotherapy, and METscore's noninvasive estimation of PD-1 blockade effectiveness in advanced NSCLC using baseline radiologic tests may have been a noninvasive measure of PD-1 blockade effectiveness.

Source link: https://europepmc.org/article/MED/35410334


Effect of acute aerobic exercise before immunotherapy and chemotherapy infusion in patients with metastatic non-small-cell lung cancer: protocol for the ERICA feasibility trial.

Patients with metastatic non-small cell lung cancer suffer from numerous signs related to disease and therapy, which may also compromise the patient's overall health. Physical exercise may improve treatment response, particularly due to its known effects on the immune system, in addition to its benefits on quality of life and exhaustion. The ERICA investigation is designed to determine the acceptability of a controlled acute physical exercise therapy that was immediately after immune-chemotherapy infusion in patients with mNSCLC. ERICA, a prospective, monocentric, randomised controlled, open-label feasibility study conducted at the Centre Léon Bérard Comprehensive Cancer Center, is a prospective, monocentric, randomised controlled, open-label feasibility study. Participants will be enrolled in a three-month program including a supervised acute physical fitness session prior to immune-chemotherapy infusion, and an activity tracker in unsupervised home-based walking program. The French ethics committee approved the research protocol. Ethics and dissemination The study's dissemination The French ethics committee approved it.

Source link: https://europepmc.org/article/MED/35393316


Early specialized palliative care for patients with metastatic lung cancer receiving chemotherapy: a feasibility study of a nurse-led screening-triggered programme.

Background: Background Information on the use of early specialized palliative care have yet to be developed. The present research examined the effectiveness of a nurse-led, screen-triggered early specialized palliative care intervention service early in the process, as well as collect data to design a randomized controlled trial. Patients with metastatic lung cancer and receiving first-line platinum-based chemotherapy were eligible. After the second course of first-line chemotherapy, the main endpoint was the completion rate of the assessment questionnaire. Improvements in Functional Assessment of Cancer Therapy-Lung scores, depression, and anxiety rates based on the Patient Health Questionnaire 9 and the Hospital Anxiety and Depression Scale, as well as the contents of specialized palliative care were among the secondary endpoints. A total of 38 patients had stage IV non-small cell lung cancer, and 12 had extensive disease small-cell lung carcinoma. Conclusions: This early specialized palliative care therapy intervention is cost-effective and may be useful in improving patients' quality of life.

Source link: https://europepmc.org/article/MED/35079813


Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060).

Lung cancer is one of the most common causes of brain metastases, and it is always associated with poor prognosis. To determine the tumor immune microenvironment, tumor immune microenvironment was determined by RNA sequencing of eighty-six samples from primary lung tumors and paired brain metastases of 43 patients. Our results showed that matched brain metastases compared to primary lung tumors showed reduced tumor infiltrating lymphocytes, a larger number of neutrophils infiltration, reduced scores of immune-related signatures, and a smaller proportion of tumor microenvironment immune type I tumors were found in comparison with primary lung tumors. In addition, we found no association between paired brain metastases and primary lung tumors, which is ineffective. Moreover, the tumor immunoenvironment between paired brain metastases and primary lung tumors in the metachronous group showed greater differences in the metachronous group than in the synchronous group. Our results show that brain metastatic tumors are more immunosuppressed than primary lung tumors, which may help guide immunotherapeutic strategies for NSCLC brain metastases.

Source link: https://europepmc.org/article/MED/35402080


The efficacy and safety of immunotherapy and palliative radiotherapy in metastatic non-small cell lung cancer patients: a systematic review and meta-analysis

Aim: Palliative radiotherapy is commonly used in the treatment of metastatic non-small cell lung cancer. However, it is also discussed whether pRT could influence the outcomes of mNSCLC patients who were using immune checkpoint inhibitors as maintenance therapy. Improved DCR, OS, and PFS were notably associated with increased DCR, OS, and PFS. Patients receiving ICIs plus pRT showed no statistically significant difference between patients in the intervention group and those in the control group in safety studies of III-IV grade adverse events. Conclusion: Patients with mNSCLC may be able to benefit from the ICI and pRT combination therapy with a low incidence of grade III-IV AEs in patients.

Source link: https://europepmc.org/article/PPR/PPR474561


Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1.

Since being approved in October 2016, immunoe checkpoint inhibitors of programmed cell death 1/programmed cell death ligand 1 have quickly adopted in U. S. clinical trials for first-line therapy of metastatic non-small cell lung cancer and programmed cell death ligand 1, but a better understanding of long-term results of ICI therapy in real-world settings outside of clinical trials is needed. We wanted to present long-term results of first-line pesozumab monotherapy in the United States oncology treatments for patients with metastatic NSCLC, PD-L1 expression 50%, and high success rate. In the spotlight cohort, median rwPFS was 7. 3 months; 88 patients had a complete or partial response; 88 patients had a rwTR of complete or partial response. Conclusions Real-world results remain consistent with those seen in clinical studies, demonstrating long-term benefits of first-line penetab monotherapy for patients with metastatic NSCLC, PD-L1 expression 50 percent, and high success status.

Source link: https://europepmc.org/article/MED/35402266


Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: A systematic review and network meta-analysis.

Pembrolizumab monotherapy has been substituted for chemotherapy as the first-line therapy for patients with metastatic non-small-cell lung cancer with tumor-programmed death-ligand 1 expression 50%. The benefit of chemotherapy and pembrolizumab is uncertain compared to pembrolizumab monotherapy. Objective response rate and adverse events were among the outcomes investigated by Endpoints, including progression-free survival and overall survival as a hazard ratio and narrowed mean survival time from Kaplan-Meier curves, as hazard ratio and reduced mean survival time as a result of patient data reconstruction, patient data, and subjective response rate and adverse events. Comparing to pembrolizumab monotherapy, combination therapy with HR and RMST produced longer PFS and similar OS as compared to pessimistic monotherapy.

Source link: https://europepmc.org/article/MED/35341985

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions